Recon: Chinese Scientist May Face Criminal Charges After Editing Babies' Genes

• The Warren bill could promote beneficial public-private partnerships in the life sciences (STAT)
• Tufts to review ties to Purdue Pharma after ‘deeply troubling’ disclosures (STAT)
• AbbVie's Imbruvica fails to meet main goal in pancreatic cancer study (Reuters) (Evaluate) (Press)
• Study Links Drug Maker Gifts for Doctors to More Overdose Deaths (NYTimes) (Reuters)
• The Insulin Wars: How insurance companies farm out their dirty work to doctors and patients (NYTimes)
• Grassley to test GOP on lowering drug prices (The Hill)
• Big Pharma Less Concerned About Industry Disruption This Year (Forbes)
• As Shutdown Enters Second Month, Public Health Risks Rise (Forbes)
• FDA's Banner Year For Approvals: Will Market Access To New Drugs Follow Suit? (Forbes)

• Chinese scientist who edited genes likely to face criminal charges (Financial Times) (Reuters) (SUSTech)
• GlaxoSmithKline chair Philip Hampton to step down (Financial Times)
• UK businesses leaning towards second Brexit vote (PMLive)
• The Biotech VC View: What Does 2019 Hold For European Health Startups? (Forbes)
• 'Well-oiled machine': how Brexit disruption could hit medicine supplies (The Guardian)
• Stockpiling insulin for no-deal: 'If I run out, I have no idea what to do' (The Guardian)
• Revealed: UK patients stockpile drugs in fear of no-deal Brexit (The Guardian)
• Trivalent gets UK green light for flu in over 65s (PharmaTimes)
• EC approves expanded label for Orkambi (PharmaLetter-$) (Press)
• NICE recommends Pierre Fabre's Braftovi in BRAF V600-mutated advanced melanoma (Pharmafile)
• Winners Of China's Centralized Procurement To Secure Over 60% Market Share (BioCentury)
• Just 10% of those harmed in clinical trials in India receive compensation (Pharmafile)
• NHS England sees off AbbVie's Hep C legal challenge (PMLive)
• Roche case against NMRA dismissed: Judgment strengthens regulator’s resolve (Daily Mirror)

• Should You Bet On Transdermal Drug Delivery? (Forbes)
• The new drugs of 2018 (C&EN)
• When Cancer Meets the Internet (NYTimes)
• What Will FDA Do With All Those “Violative” Stem Cell Clinics Once Enforcement Discretion Tolls in November 2020? (FDA Law Blog)
• Pro-Vaccination Message Should Be Apolitical, As NYT Argues But Fails To Demonstrate (Forbes)
• Swiss team develop 'microswimmer' robot to deliver drugs through the body (Reuters)
• Possible link seen between opioids and a birth defect that's on the rise (CBS)
• Q4 Pharma Earnings Preview: J&J, Bristol And AbbVie (Scrip-$)
• Immunocore lifer leaves to head research at TCR rival Scancell (Fierce)
• Novo Holdings' antibiotic resistance fund backs 3 biotechs (Fierce)
• How CAR-Ts Are Changing The Lifecycle Paradigm For ATMPs (Pink Sheet-$)
• FDA's OTC Naloxone Model Labels Confirmed In CONFER Study (Pink Sheet-$)
• Insomnia treatment may help ease depression during menopause (Reuters)
• ALS researchers at Harvard uncover new biomarker and drug target (Fierce)
• Prinston Pharmaceutical Inc. issues Voluntary Nationwide Recall of Irbesartan and Irbesartan HCTZ Tablets Due to detection of a Trace Amount of Unexpected Impurity, N- nitrosodiethylamine (NDEA) in the Products (FDA)

• Johnson & Johnson, AbbVie superstar Imbruvica flunks pancreatic cancer test (Fierce)
• Antibe Therapeutics Receives Approval to Initiate Part Two of Phase 2B Dose-Ranging, Efficacy Study for ATB-346 (Press)
• Redx cleared to start Wnt cancer trial again after safety scare (Fierce)
• BerGenBio Announces Start of Phase I Trial Evaluating ADCT-601, a Novel Anti-AXL ADC, in Patients With Advanced Solid Tumours (Press)
• Lilly Phase 3 REACH-2 Trial Data Published in The Lancet Oncology Shows Improvement in Overall Survival with CYRAMZA® (ramucirumab) in Second-Line AFP-High Hepatocellular Carcinoma Patients (Press)

• Fitbit and NIH boost precision medicine research partnership (MedCityNews)
• Verily's research wearable lands FDA clearance for on-demand ECG (mobihealthnews)

• The US Biosimilars Patent Litigation Outlook For 2019 (Law360-$)
• BIO's Comment on Advanced Notice of Proposed Rulemaking Regarding Review of Controls for Certain Emerging Technologies (BIO)
• FDA chief threatens to take e-cigarettes off the market (NBC)
• FDA: Level of young people addicted to vaping may require drug therapies (The Hill)
• Hospitals Stopped Readmitting So Many Medicare Patients. Did That Cost Lives? (NYTimes)
• Shopko Bankruptcy Puts 146 Pharmacies In Play For CVS, Walgreens And Kroger (Forbes)
• FDA May Call Back Furloughed Staff for Food-Safety Checks (Bloomberg)
• Theranos Execs' Days Of Reckoning Draw Nearer (Law360-$)
• UnitedHealth Sues Generic-Drug Makers For Price-Fixing (Law360-$)
• PTAB Denies Novartis' Challenge To Cancer Drug Patents (Law360-$)
• Breast Implant Litigation – The Defense Wins a … Couple (Drug & Device Law)
• Trump administration approves Medicaid work requirements in Arizona (The Hill)

• FDA Advisory Committee Calendar

• Irish $1.9bn Tax Bill 'Out Of Nowhere' Perplexes Perrigo, Troubles Analysts (Pink Sheet-$)

• Rare But Real: How One Startup Is Willing Itself To Lift China Orphan Drug Market (Scrip-$)
• Aum Bets On Asia-To-Global Oncology Model (Scrip-$)

• Why Sun Pharma is under a cloud: Decoding Aditya Medisales link (Economic Times)
• Sun sinks 13% after reports of 2nd whistleblower letter (Economic Times)
• Sub-committee on compensation related to medical devices to meet industry associations next week (PharmaBiz)
• MSF, Lawyers Collective seek removal of Rule 3(f) from draft Patents Amendment Rules 2018 (PharmaBiz)
• Lupin, Sun Pharma, Glenmark recall products in US (Economic Times)
• Wockhardt gets USFDA nod for generic cancer drug (Economic Times)
• India bans 80 more FDCs, calling them ‘irrational’ and ‘unjustified’ (PharmaLetter-$)

• Dr. John Mendelsohn, 82, Researcher Who Led Top Cancer Center, Dies (NYTimes)
• Helping Children Conquer Chronic Pain (NYTimes)